Stock futures rose after Nvidia's stronger-than-expected earnings report and outlook. Just after 6 p.m. in New York, Nasdaq futures rose 1%, while S&P 500 futures rose 0.6%, and Dow Jones Industrial ...

What began as a banner day for stocks turned into a major rout, as investors signaled ongoing skepticism about the longevity of the artificial intelligence boom and trimmed hopes of support from the ...

Pretty much everything rallied on Friday as Wall Street shook off yesterday’s technology stock selloff. The Dow Jones Industrial Average rose 493 points, or 1.1%. The S&P 500 was up 1%. The Nasdaq ...

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks. This was a complete exit from Cidara ...

Here are the top stories to read during Wednesday's trading: ...

Here are the top stories to read Thursday: ...

The seemingly sturdy U.S. stock market has begun to wobble. Its months'-long tech-driven rally may be running out of steam amid growing wariness about the artificial intelligence boom and broader ...

The big news Tuesday was crypto not just posting gains, but also rising even as U.S. stocks sold off. That outperformance has been rare for what seems like months, with bitcoin and other ...

An intensifying selloff in bank and tech stocks dragged major indexes lower Monday, even after Warren Buffett's Berkshire Hathaway disclosed a major bet on Google-parent Alphabet. The declines ...

U.S. markets dropped for a fourth straight session, as both highflying tech stocks such as Nvidia and old-economy companies like Home Depot came under pressure. The S&P 500 and Dow industrials both ...

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year. Merck is paying $221.50 cash per share of Cidara, a San ...